The new FDA draft guidance issued last during the second week of November demonstrates that FDA does not want institutional review boards (IRBs) to lose their critical role in the clinical research process. The new guidance, issued in November 2012 entitled “IRB...
According to Ciaran Murray, the CEO of Icon, large-scale CRO consolidation will not be at the level of past years in 2012. According to Murray, the industry will take a step back and digest the moves from previous years, although companies will still be active in...
